{"name":"AlgoTherapeutix","slug":"algotherapeutix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATX01 10%","genericName":"ATX01 10%","slug":"atx01-10","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ATX01 15%","genericName":"ATX01 15%","slug":"atx01-15","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ATX01 10%","genericName":"ATX01 10%","slug":"atx01-10","phase":"phase_2","mechanism":"ATX01 10% is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ATX01 15%","genericName":"ATX01 15%","slug":"atx01-15","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPMWdMTTRLVnZXYTgzYmtkQ0E2ZlJjQlA4S2s0amJ6OF9uM2VMcFdHdS1fdC1kTWg2alVmUjZlakcwNzJfenpfZmJnckxGZDZBT1Rub0NkTXByazEzREowUDd2NzN0QUhsZHAyVFBNZmxzMUx4MElxRmlpRklqSXlfcmFadjJ4SFhHOEdRUFh2blV5b0N6Y29YaS1QTGliV3NtMGxpYzhFRkozWHB0Uk15YzVpYVQzYXdaajZTMUZtUkZ2U3lzdTg2OUdyR3FlYm9SYXVUU2U4UlFtZ0s0YzlwTVl5VnZTVU9IRnMxYWVlSy1qMWpFa2hyQmFVS215ZS1XbmVTcnlJQXBOeUZ4NHdlNl82RzFEQ29MSkV5ZFEtdTVCU2lMaWF5Qw?oc=5","date":"2026-01-20","type":"trial","source":"GlobeNewswire","summary":"Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: - GlobeNewswire","headline":"Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1UTzZFMkpBUUxQbmNERjVHUTFUTkd5Q2gzYWluSVhmTEhWWUlzc0xHMVdOVWxob1E4QXF3OXdlcklnekxxRFFsZGd5SkxOSjJ2QnU0?oc=5","date":"2025-02-18","type":"trial","source":"FirstWord Pharma","summary":"AlgoTx's chemo-induced neuropathy therapy falls short in mid-stage study - FirstWord Pharma","headline":"AlgoTx's chemo-induced neuropathy therapy falls short in mid-stage study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQNE9LYnNpR1otdjBNLXBGWWpOMkFhNGt0c2tnQWVmZVIxZjFoS2pNclFTQ1NyWHVfcVd6ejhpYllNckJfNWZsRWpTZ1loeVdoank1QmNaN0lRYVZCVWp5Y3RHMFhnVFI1UVNiemViQmdNS3pWTzBKWUVRTEdQRjB4dndjQzdMdm5zbW4wdWtRX3dENGIzTDJuRHJxWExXZXZjLUxWNlYyQXVBOXhCYXJmY29fczRaSGoydndvRXpsYUJVNElQREE?oc=5","date":"2021-11-22","type":"trial","source":"fiercepharma.com","summary":"Topical treatment for chemotherapy pain clears early clinical test, teeing up further study of alternative to oral options - fiercepharma.com","headline":"Topical treatment for chemotherapy pain clears early clinical test, teeing up further study of alternative to oral optio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}